Fierce Pharma

SEPTEMBER 11, 2024

For Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming. | Ahead of an advisory committee meeting slated for Friday, the FDA unleashed damning briefing documents calling into question the effectiveness and safety of Intercept’s rare liver disease drug Ocaliva. The regulator specifically raised an eyebrow at the post-marketing trials Intercept has used in a bid to keep hold of the accelerated approval it won back in 2016.

FDA 278

FDA Safety Pharmaceutical Marketing 278

MedCity News

SEPTEMBER 11, 2024

More than 330 provider organizations signed letters this week urging the White House and Congress to extend a pandemic-era telehealth prescribing flexibility. Failure to extend this policy would cause millions of Americans to lose access to treatment, they argued. The post 300+ Provider Organizations Urge Feds to Prevent Leaked DEA Rule From Going into Effect appeared first on MedCity News.

128

128

Fierce Pharma

SEPTEMBER 11, 2024

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara. | Tremfya will enter the UC space as J&J’s older Stelara, which is approved to treat both forms of IBD, nears biosimilar competition and Inflation Reduction Act-mandated price concessions.

Competition 264

Competition FDA 264

MedCity News

SEPTEMBER 11, 2024

By surfacing conversational, behavioral, and environmental insights at the point of care — and enabling data-driven operational decisions — AI has the power to transform individual patient experiences and drive systemic improvements in care quality and efficiency. The post The New Role of Engagement: Surfacing Insights at the Point of Care and Beyond appeared first on MedCity News.

Patients 125

Patients Physicians 125

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

SEPTEMBER 11, 2024

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease | More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important disease areas—first-line non-small cell lung cancer.

Competition 208

Competition FDA 208

pharmaphorum

SEPTEMBER 11, 2024

A machine-learning tool developed by AstraZeneca and trained on UK Biobank data, called MILTON, can predict over 1,000 diseases, before diagnosis

Training 122

Training 122

MedCity News

SEPTEMBER 11, 2024

More than 4 million Highmark commercial members now have access to AppliedVR’s RelieVRx as a covered therapeutic. The post Highmark Covers AppliedVR’s Product for Chronic Low Back Pain appeared first on MedCity News.

122

122

Fierce Pharma

SEPTEMBER 11, 2024

Last week, Zydus Lifesciences confirmed the receipt of an FDA warning letter at its Waghodia plant in Gujarat, India, marking the latest in a string of production reprimands for the India | Last week, Zydus Lifesciences confirmed the receipt of an FDA Warning Letter at its Waghodia plant in Gujarat, India, marking the latest in a string of production reprimands for the Indian drugmaker.

FDA 147

FDA 147

MedCity News

SEPTEMBER 11, 2024

Securities regulators say the role of Ipsen employee Dishant Gupta made him privy to details of the Epizyme acquisition. Gupta allegedly accumulated Epizyme shares while the deal was negotiated, then sold all of them hours after the transaction was announced. The post SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition appeared first on MedCity News.

Biopharma 121

Biopharma Pharma 121

Fierce Pharma

SEPTEMBER 11, 2024

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and Regeneron as the Dupixent partners look to expand the reach of Dupixent into several new diseases.

130

130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

pharmaphorum

SEPTEMBER 11, 2024

One in two UK doctors would not use GenAI to treat patients, but there was more willingness to use it for diagnostic purposes, survey finds

Doctors 111

Doctors Patients 111

Pharmaceutical Technology

SEPTEMBER 11, 2024

As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, a prodrug approach emerges to potentially address dosing challenges.

Side effects 111

Side effects 111

Pharmaceutical Commerce

SEPTEMBER 11, 2024

The latest news for pharma industry insiders.

Pharma 104

Pharma Medicine 104

European Pharmaceutical Review

SEPTEMBER 11, 2024

Sanofi has inaugurated a new production unit in France which utilises a world-first modular concept. The site, Modulus, located in Neuville-sur-Saône (Rhône-Alpes), is supported by an investment of nearly €500 million and will produce Sanofi’s next vaccines and biologic drugs. Modulus can adapt to manufacture up to four vaccines simultaneously. Notably, reconfiguration of the technological platform (live attenuated viral vaccines, recombinant protein or messenger RNA vaccines, as well as treatme

Medicine 103

Medicine Manufacturing Pharmaceutical Patients 103

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaTimes

SEPTEMBER 11, 2024

New evidence highlights AI’s potential in early lung cancer detection

102

102

Pharma IQ

SEPTEMBER 11, 2024

Explore how the pharmaceutical industry is addressing its carbon footprint through sustainable sourcing, supply chain decarbonization, and data-driven strategy.

Pharmaceutical 100

Pharmaceutical 100

PharmaTimes

SEPTEMBER 11, 2024

Patients with relapsed multiple myeloma gain access to life-extending therapy

Patients 100

Patients 100

Pharmaceutical Commerce

SEPTEMBER 11, 2024

The parties’ want to provide customers with a “one-stop-shop,” with the hopes that their services will be easier to navigate.

98

98

Advertisement

PharmaVoice

SEPTEMBER 11, 2024

A handful of potential blockbusters are marching toward FDA review.

FDA 98

FDA 98

MedCity News

SEPTEMBER 11, 2024

HLTH 2024, scheduled for October 20-23 at the Venetian Expo Center in Las Vegas, will highlight new programming, a physicians roundtable, generative AI, the shifting landscapes of telemedicine, retail health, women’s health, and lots more. The post Get Ready for HLTH 2024: A Preview Guide appeared first on MedCity News.

Retail 80

Retail Physicians 80

PharmaVoice

SEPTEMBER 11, 2024

A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.

Pharma 98

Pharma Leads 98

Pharmaceutical Technology

SEPTEMBER 11, 2024

EASD 2024 participants are looking for the hottest efficacy data to make predictions on the next trend in the metabolic space.

78

78

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

SEPTEMBER 11, 2024

A direct-to-patient model for observational research will ease the participation burden, better incorporate the patient voice, and empower individuals to take control of their health – all while meeting the growing demands for robust evidence in developing new drugs and therapeutics. The post A Tailor-made Approach to Simplify Observational Research appeared first on MedCity News.

Patients 72

Patients Pharmaceutical Biopharma Pharma 72

PharmaTech

SEPTEMBER 11, 2024

During a presentation at the PDA/FDA Joint Regulatory Conference, Nicholas Violand of Johnson & Johnson and Paul Palmer of Paul R. Palmer Limited discussed how aging facilities can impact the quality of pharmaceutical products.

FDA 69

FDA Pharmaceutical products Pharmaceutical 69

pharmaphorum

SEPTEMBER 11, 2024

Viridian's thyroid eye disease drug veligrotug clears its first phase 3 trial, with data suggesting it could be competitive with Amgen's Tepezza

Competition 69

Competition 69

Pharmacy Times

SEPTEMBER 11, 2024

The DEA will have a hearing in December 2024 regarding the potential reclassification of cannabis to Schedule III, which could significantly impact the regulatory environment for pharmacies and their involvement in the cannabis market.

Marketing 57

Marketing 57

Advertisement

Distribution

pharmaphorum

SEPTEMBER 11, 2024

A clinical trial has backed the safety and efficacy of Novo Nordisk's weight-loss drug Saxenda in children as young as six with obesity.

Safety 64

Safety 64

Pharmacy Times

SEPTEMBER 11, 2024

The company also submitted data from the ongoing phase 2 study, demonstrating the improvements of the investigational drug for symptoms of overall disease severity.

FDA 55

FDA 55

pharmaphorum

SEPTEMBER 11, 2024

Roivant reveals its latest company, Pulmovant, which will develop a pulmonary hypertension drug licensed from Bayer in a $294m deal.

64

64

Pharmacy Times

SEPTEMBER 11, 2024

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.

55

55

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales